Trial Profile
A Randomized, Double-Blind Placebo-Controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Octreotide (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours
- Focus Registrational; Therapeutic Use
- Acronyms RADIANT-2
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Apr 2017 Results of open-label extension phase (n=170) published in the Annals of Oncology
- 07 Nov 2016 Results of a pharmacokinetic analysis published in the Clinical Pharmacology and Therapeutics
- 03 Jun 2014 Pooled analysis assessing incidence of stomatitis and correlation with efficacy presented at the 50th Annual Meeting of the American Society of Clinical Oncology.